Moleculin Biotech, Inc.
MBRX
$7.59
$0.9614.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.10% | -4.78% | -9.23% | -12.28% | -16.23% |
| Depreciation & Amortization | -13.85% | -6.87% | -3.85% | -1.56% | 4.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.27% | -8.25% | -7.32% | -10.09% | 4.17% |
| Operating Income | 16.27% | 8.25% | 7.32% | 10.09% | -4.17% |
| Income Before Tax | -71.51% | -15.19% | 14.96% | 28.29% | -13.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.51% | -15.19% | 14.96% | 28.29% | -13.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.51% | -15.19% | 14.96% | 28.29% | -13.18% |
| EBIT | 16.27% | 8.25% | 7.32% | 10.09% | -4.17% |
| EBITDA | 16.28% | 8.26% | 7.34% | 10.13% | -4.16% |
| EPS Basic | 76.22% | 68.53% | 54.57% | 52.14% | 11.82% |
| Normalized Basic EPS | 76.22% | 68.53% | 54.57% | 52.14% | 11.82% |
| EPS Diluted | 76.22% | 68.53% | 54.57% | 52.14% | 11.82% |
| Normalized Diluted EPS | 76.22% | 68.53% | 54.57% | 52.14% | 11.82% |
| Average Basic Shares Outstanding | 528.04% | 276.01% | 144.34% | 74.29% | 37.98% |
| Average Diluted Shares Outstanding | 528.04% | 276.01% | 144.34% | 74.29% | 37.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |